Dysbiosis in Phylogenetically Diverse Species Associated With Type 2 Diabetes
By Elana Gotkine HealthDay Reporter
WEDNESDAY, June 26, 2024 -- The gut microbiome has a potential functional role in the pathogenesis of type 2 diabetes (T2D), according to a study published online June 25 in Nature Medicine.
Zhendong Mei, Ph.D., from Brigham and Women's Hospital in Boston, and colleagues analyzed 8,117 shotgun metagenomes from 10 cohorts of individuals with T2D, prediabetes, and normoglycemic status in the United States, Europe, Israel, and China in a comprehensive study of the T2D microbiome.
The researchers identified associations between dysbiosis in 19 phylogenetically diverse species with T2D; for example, enriched Clostridium bolteae and depleted Butyrivibrio crossotus. These microorganisms also contributed to community-level functional changes that may underlie pathogenesis of T2D, such as perturbations in glucose metabolism. Within-species phylogenetic diversity was identified for strains of 27 species that account for inter-individual differences in T2D risk; these were explained by strain-specific gene carriage in some cases, including loci involved in various mechanisms of horizontal gene transfer and novel biological processes underlying metabolic risk.
"Although our study does not establish causal linkages and should be interpreted as hypothesis generating, it offers the most comprehensive evidence to date of the gut microbiome's involvement in the pathogenesis of T2D from the population study perspective," the authors write. "These results lay the groundwork for future mechanistic studies."
One author disclosed ties to Zoe Nutrition, Empress Therapeutics, and Seres Therapeutics.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2024
Read this next
ADA: Weight Loss, Type 2 Diabetes Remission Up With Replacing Diet Drinks With Water
WEDNESDAY, June 25, 2025 -- For adult women with overweight or obesity and type 2 diabetes (T2D), replacing diet beverages (DBs) with water is associated with greater weight loss...
ADA: Orforglipron Reduces Glycated Hemoglobin in Early Type 2 Diabetes
WEDNESDAY, June 25, 2025 -- The oral small-molecule glucagon-like peptide-1 receptor agonist, orforglipron, reduced glycated hemoglobin (HbA1c) over 40 weeks in adults with early...
ADA: Ecnoglutide Yields Superior, Sustained Reduction in Body Weight
MONDAY, June 23, 2025 -- For adults with obesity or overweight without diabetes, the novel cyclic adenosine monophosphate-biased glucagon like peptide 1 receptor agonist...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.